HIV PrEP CAB-LA Italy: Early Results
- Despite significant progress in HIV prevention strategies, over 100,000 new HIV diagnoses are still reported annually within teh World Health Institution European Region.
- Between December 2024 and August 2025, two specialized HIV/sexually transmitted infection centers in Italy initiated a program offering long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) to 265...
- The program specifically targeted individuals facing challenges with conventional oral PrEP,including those with potential adherence issues,co-existing health conditions,or structural/behavioral barriers to consistent medication use.
Long-Acting HIV Prevention Shows Promise in Real-World European Setting
Table of Contents
Published October 4, 2025
Addressing Ongoing HIV Diagnoses in Europe
Despite significant progress in HIV prevention strategies, over 100,000 new HIV diagnoses are still reported annually within teh World Health Institution European Region. This underscores the continued need for innovative prevention tools and approaches.
Real-World Data on Cabotegravir Long-Acting (CAB-LA) for PrEP
Between December 2024 and August 2025, two specialized HIV/sexually transmitted infection centers in Italy initiated a program offering long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) to 265 individuals. This implementation followed the 2024 recommendation for CAB-LA in European guidelines, but represents some of the first real-world data collected outside of clinical trials within Europe.
The program specifically targeted individuals facing challenges with conventional oral PrEP,including those with potential adherence issues,co-existing health conditions,or structural/behavioral barriers to consistent medication use.
Initial Findings on Adherence and Safety
Early results, as detailed in a recent rapid dialog, focus on the characteristics of participants, their motivations for choosing CAB-LA, and initial outcomes related to adherence, how well the medication was tolerated, safety profiles, and reasons for any treatment discontinuations. further analysis will provide a more comprehensive understanding of the long-term effectiveness and impact of this preventative measure.